Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567229 | 0.94 | CYP1A2 (0.52) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL11533429 | 0.91 | CYP2C9 (0.65) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL8602062 | 0.84 | CYP2C9 (0.59) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL24575913 | 0.84 | MEN1 (0.65) | TRPV1CA2CAMK2ASMN1; SMN2MTOR | |
| SCHEMBL3457884 | 0.82 | TSHR (0.57) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL3662909 | 0.82 | SMN1; SMN2 (0.71) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL258716 | 0.82 | CYP2C9 (0.62) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL27866 | 0.81 | CYP2D6 (0.80) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL3278767 | 0.80 | CYP2C9 (0.55) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL1694370 | 0.80 | L3MBTL1 (0.62) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773540-B1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240197694-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-06-20 | — | — | US | disclosed |
| WO-2024117179-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2024-06-06 | — | — | WO | disclosed |
| US-20240174959-A1 | NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-4361249-A1 | NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | Mochida Pharmaceutical Co., Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132854-A1 | NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4351650-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NanoPharmaceuticals LLC (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347563-A1 | 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2024-04-10 | — | — | EP | disclosed |
| EP-2118081-A2 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | Kainos Medicine, Inc., (KR) | 2009-11-18 | — | — | EP | disclosed |
| EP-2079743-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
| EP-1996541-A1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008087560-A2 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | KAINOS MEDICINE, INC., (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007103996-A1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007035154-A1 | NOVEL N-PYRAZINIL-PHENYLSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | CYP1A2 495/4885CYP2D6 677/4885CYP2C9 1542/4885 |
| US-20240197694-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | DCAF1, DDB1, CUL4A | CYP1A2 4353/4885CYP2D6 4251/4885CYP2C9 4368/4885 |
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F12 | CYP1A2 224/4885CYP2D6 300/4885CYP2C9 48/4885 |
| US-20240132854-A1 | NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | IAPP, COG6, IL6 | CYP1A2 4881/4885CYP2D6 4396/4885CYP2C9 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.